U.K. Cardiac Resynchronization Therapy Market Size & Outlook
- MedTech
- Cardiovascular Devices
- Cardiac Resynchronization Therapy Market Outlook
- Cardiovascular Devices
Global Report
Related Markets
Ask a question about the cardiac resynchronization therapy market
UK cardiac resynchronization therapy market highlights
- The UK cardiac resynchronization therapy market generated a revenue of USD 203.7 million in 2025 and is expected to reach USD 344.4 million by 2033.
- The UK market is expected to grow at a CAGR of 6.8% from 2026 to 2033.
- In terms of segment, crt-defibrillator was the largest revenue generating product in 2025.
- CRT-Pacemaker is the most lucrative product segment registering the fastest growth during the forecast period.
Cardiac resynchronization therapy market data book summary
| Market revenue in 2025 | USD 203.7 million |
| Market revenue in 2033 | USD 344.4 million |
| Growth rate | 6.8% (CAGR from 2026 to 2033) |
| Largest segment | Crt-defibrillator |
| Fastest growing segment | CRT-Pacemaker |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CRT-Defibrillator, CRT-Pacemaker |
| Key market players worldwide | Medtronic PLC, Abbott Laboratories, Boston Scientific Corp, BIOTRONIK, MicroPort Scientific Corp, LivaNova PLC |
Other key industry trends
- In terms of revenue, UK accounted for 4.0% of the cardiac resynchronization therapy market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany cardiac resynchronization therapy market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 344.4 million by 2033.
High incidence and prevalence of heart failure can lead to Sudden Cardiac Arrest (SCA) and death. Implantation of CRT device may, thus, be prescribed to prevent SCA in patients at high risk. As per the National Institute for Health and Care Excellence (NICE), over 920,000 people suffered from chronic heart failure in the UK in 2018.
The growing prevalence of risk factors leading to heart failure is the main factor estimated to contribute to higher demand for CRT devices in the coming years. Risk factors for heart failure are coronary heart disease, high blood pressure, cardiomyopathy, arrhythmias, and congenital heart diseases.
No credit card required*
Publish Date: Nov 11, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Resynchronization Therapy Market Scope
Cardiac Resynchronization Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Medtronic PLC | View profile | 95,000 | Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 | www.medtronic.com |
| Boston Scientific Corp | View profile | 48,000 | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 | www.bostonscientific.com |
| LivaNova PLC | View profile | 2,900 | 20 Eastbourne Terrace, London, United Kingdom, W2 6LG | www.livanova.com |
| BIOTRONIK | View profile | 5001-10000 | Berlin, Berlin, Germany, Europe | www.biotronik.com/de-de |
| MicroPort Scientific Corp | View profile | 8,230 | 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, China, People's Republic of, 201203 | www.microport.com |
U.K. Cardiac Resynchronization Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cardiac Resynchronization Therapy Market Outlook will help companies and investors design strategic landscapes.
Crt-Defibrillator was the largest segment with a revenue share of 74.03% in 2025.
Horizon Databook has segmented the U.K. cardiac resynchronization therapy market based on crt-defibrillator, crt-pacemaker covering the revenue growth of each sub-segment from 2021 to 2033.
High incidence and prevalence of heart failure can lead to Sudden Cardiac Arrest (SCA) and death. Implantation of CRT device may, thus, be prescribed to prevent SCA in patients at high risk. As per the National Institute for Health and Care Excellence (NICE), over 920,000 people suffered from chronic heart failure in the UK in 2018.
The growing prevalence of risk factors leading to heart failure is the main factor estimated to contribute to higher demand for CRT devices in the coming years. Risk factors for heart failure are coronary heart disease, high blood pressure, cardiomyopathy, arrhythmias, and congenital heart diseases.
- U.K. Cardiac Resynchronization Therapy Market Product Outlook (Revenue, USD Million , 2021-2033)
- CRT-Defibrillator
- CRT-Pacemaker
- U.K. Cardiac Resynchronization Therapy Market End-Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Cardiac Centers
- Others
Reasons to subscribe to Cardiac Resynchronization Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cardiac Resynchronization Therapy Market Outlook databook
- Our clientele includes a mix of Cardiac Resynchronization Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Cardiac Resynchronization Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Cardiac Resynchronization Therapy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.K. Cardiac Resynchronization Therapy Market, 2021-2033 (US$M)
UK cardiac resynchronization therapy market statistics, by product, 2021-2033 (US$M)
